Stock listing

SIGHT Stock Price, News, Filings & Events — Gensight Biologics Sa

Selected listing: SIGHT · EURONEXT · EUR · FR

This page tracks Gensight Biologics Sa's SIGHT:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following SIGHT:EURONEXT. SIGHT:EURONEXT is the stock-level entry point for investors researching Gensight Biologics Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Gensight Biologics Sa is a public company listed under the ticker SIGHT on the French market. The company has a market capitalization of approximately €22.3 million. Gensight focuses on developing innovative gene therapies for retinal diseases.

SIGHT:EURONEXTEURFRUpdated September 25, 2026
Gensight Biologics Sa logo
Ticker
SIGHT:EURONEXT
Asset type
Stock
Market cap
$35.2M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
EURONEXT
Currency
EUR

Gensight Biologics Sa SIGHT:EURONEXT stock context

This page tracks Gensight Biologics Sa's SIGHT:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following SIGHT:EURONEXT. SIGHT:EURONEXT is the stock-level entry point for investors researching Gensight Biologics Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Gensight Biologics Sa is a public company listed under the ticker SIGHT on the French market. The company has a market capitalization of approximately €22.3 million. Gensight focuses on developing innovative gene therapies for retinal diseases.

Latest news from Gensight Biologics Sa

All Gensight Biologics Sa news →

Research Gensight Biologics Sa

Alternate listings